



**Eledon**  
Pharmaceuticals

## **Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference**

November 29, 2023

IRVINE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming NobleCon19 - Noble Capital Markets' 19<sup>th</sup> Annual Emerging Growth Equity Conference on Monday, December 4, 2023, at 12:00 p.m. EST. Dr. Gros will also participate in a panel discussion titled: *The Organ Transplant Revolution*, that will take place on Monday, December 4, 2023, at 5:00 p.m. EST. The NobleCon19 conference will take place December 3-5, 2023, in Boca Raton, Florida.

A video webcast of the company overview presentation will be available the following day on the Company's website at <https://ir.eledon.com/news-and-events/events>, and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website: [www.nobleconference.com](http://www.nobleconference.com) and on Channelchek: [www.channelchek.com](http://www.channelchek.com), the investor portal created by Noble. The webcast will be archived on Eledon's website, the NobleCon website, and on [Channelchek.com](http://Channelchek.com) for 90 days following the event.

### **About Eledon Pharmaceuticals and tegoprubart**

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company's website at [www.eledon.com](http://www.eledon.com).

Follow Eledon Pharmaceuticals on social media: [LinkedIn](#); [Twitter](#)

### **Investor Contact:**

Stephen Jasper  
Gilmartin Group  
(858) 525 2047  
[stephen@gilmartinir.com](mailto:stephen@gilmartinir.com)

### **Media Contact:**

Jenna Urban  
Berry & Company Public Relations  
(212) 253 8881  
[jurban@berrypr.com](mailto:jurban@berrypr.com)

Source: Eledon Pharmaceuticals



**Eledon**  
Pharmaceuticals

Source: Eledon Pharmaceuticals, Inc.